2023 Evaluating Biopharma Schedule of Events
SEPTEMBER 21, 2023
SMART(ER) BIOMANUFACTURING: EVALUATING THE RISKS AND OPPORTUNITIES
Advances in manufacturing 4.0 including digitalization, AI, and machine learning offer biopharmaceutical company’s unique opportunities to overhaul antiquated processes to increase productivity, flexibility, and reduced cost. However, as with each great innovation, there are risks, uncertainties, and challenges. Our experts share their individual experiences and insight to help your anticipate challenges and implement better manufacturing strategies to accelerate success.
Case Study #1: Connecting Technology, Culture, and Strategy to Support Success
Case Study #2: Focusing on the Facility – Structure, Digitalization, Processes
Case Study #3: Harnessing Data and Digital Technologies to Accelerate Manufacturing Efficiencies
OCTOBER 19, 2023
CONTINUOUS BIOPROCESSING
With competition heating up, companies are now looking at cost savings. Process intensification and optimization via continuous processing fills this urgent need. However, despite the promise of increased productivity, the industry is still slow to adopt continuous processing at clinical or manufacturing scale. Our experts share their personal experiences and insight to help your anticipate challenges and implement better continuous/optimization strategies to accelerate success.
Case Study #1: Why a Truly Continuous Downstream Process Has Been so Elusive
Case Study #2: The Path to Continuous Starts with an Intensification Strategy
Case Study #3: Labor Challenges and Considerations When Implementing a Continuous Process
NOVEMBER 16, 2023
ACCELERATING ANALYTICAL DEVELOPMENT: OPTIMIZING BIOTHERAPEUTIC DEVELOPMENT EFFICIENCY
Today’s analytical groups are facing increased pressure to deliver key studies faster than ever before – and at lower costs. Scientists must evaluate best practices, exchange ideas, integrate new technologies to improve and accelerate existing analytical methods to support business goals. Our experts share their personal experiences and insight to help you overcome existing challenges and implement better strategies.
Case Study #1: How to Reduce Analytical Lifecycle Steps to Improve Product Development
Case Study #2: Implementing PAT Advances to Transition to Digital Manufacturing
Case Study #3: Identifying Opportunities and Challenges in Analytical Method Lifecycle Management
DECEMBER 14, 2023
CELL THERAPY MANUFACTURING: AUTOLOGOUS VS. ALLOGENEIC STRATEGIES
While related, scaling autologous and allogeneic cell therapies require vastly different manufacturing approaches, equipment, and technologies. Regardless of the platform chosen, implementing the right strategy early is the key to success. Our experts share their personal experiences and insight to help you anticipate challenges and implement better cell therapy strategies.
Case Study #1: Selecting the Right Technologies and Equipment to Support Your Cell Therapy Strategy
Case Study #2: Identifying Cost Savings to Improve Autologous Manufacturing Efficiency
Case Study #3: Keys to Implementing the Right Manufacturing Strategy
TBA
GENE THERAPY MANUFACTURING: IDENTIFYING THE RIGHT COMMERICIAL STRATEGY
As a next-gen therapeutic, today’s gene therapy manufacturers often adopt existing platforms, strategies, and technologies to support production goals. However, to be successful, the industry must establish and implement next-gen tools and systems to better support and economically deliver product at commercial scale. Our experts share their personal experiences and insight to help your anticipate challenges and implement better commercial strategies to accelerate success.
Case Study #1: Identifying and Implementing Next-Gen Manufacturing Platforms
Case Study #2: Challenges and Lessons Learned Scaling an AAV Production Process
Case Study #3: Addressing AAV Manufacturing Challenges for Rare Diseases
TBA
CELL LINE OPTIMIZATION: LEVERAGING TECHNOLOGY TO IMPROVE SPEED, QUALITY, COST
Developing and engineering recombinant protein expression platforms are not for the faint of heart. Many variables must be considered during the development process. When cell line challenges arise, scientists must engineer solutions to overcome. Our experts share their personal experiences and insight to help you identify and overcome today’s cell line challenges.
Case Study #1: Identifying CLD Process Improvements to Decrease Timelines and Increase Throughput
Case Study #2: Leveraging Technology to Improve Cell Line Stability and Development
Case Study #3: Considering Alternative Hosts to Improve Speed, Quality, Costs
Case Study #4: Implementing Novel Approaches to Support Next-Gen Cell Line Development
TBA
PURIFICATION: NEW TECHNOLOGIES AND STRATEGIES TO SUPPORT COMPLEX MOLECULES
Newer and more complex molecules often complicate existing downstream processes. New, innovative technologies are necessary to ensure safe, efficient, and effective capture and purification of emerging modalities. Our experts share their personal experiences and insight to help anticipate challenges and chose appropriate technologies to support your downstream strategies.
Case Study #1: Purification Strategies to Support New Therapeutic Modalities
Case Study #2: Optimizing Purifications of Challenging Drug Targets
Case Study #3: Re-evaluating Downstream Strategies to Accommodate Large Increases in Vector
Case Study #4: Leveraging Transformative Technologies to Overcome Downstream Challenges